^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral replication inhibitor

    Related drugs:
    3d
    Effect of Pradefovir Combined With Interferon on the Clinical Cure Rate in Chronic Hepatitis B: A Prospective, Multicenter, Two-Arm, Observational Cohort Study (ChiCTR2600117049)
    P=N/A, N=258, Recruiting, The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university
    New trial
    3d
    Research on the Synergistic Antitumor Mechanism of Carrimycin and Siglec-15 Nucleic Acid Aptamer Based on Intelligent Response and Targeted Delivery (ChiCTR2500113721)
    P=N/A, N=352, Not yet recruiting, Ningbo Medical Centre Lihuili Hospital; Ningbo Medical Centre Lihuili Hospital
    New trial
    |
    carrimycin
    3d
    ​​Evaluation of the Antiviral Efficacy of Pradefovir Mesylate in a Non-advantaged Population with Chronic Hepatitis B (ChiCTR2500112207)
    P4, N=172, Recruiting, Xixi Hospital of Hangzhou; Xixi Hospital of Hangzhou
    New P4 trial
    6d
    This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (clinicaltrials.gov)
    P2, N=0, Withdrawn, Traws Pharma, Inc.
    New P2 trial
    6d
    To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring (clinicaltrials.gov)
    P2, N=360, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    13d
    A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=66, Completed, Traws Pharma, Inc. | Recruiting --> Completed | N=32 --> 66
    Trial completion • Enrollment change
    19d
    Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Aligos Therapeutics
    New P1 trial
    19d
    Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Aligos Therapeutics
    New P1 trial
    22d
    PULSE-US: A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe (clinicaltrials.gov)
    P=N/A, N=131005, Completed, Pfizer | N=84584 --> 131005
    Enrollment change • HEOR
    1m
    A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants (clinicaltrials.gov)
    P1, N=0, Withdrawn, Pfizer | N=28 --> 0 | Trial completion date: Jun 2025 --> Dec 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2025 --> Dec 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    2ms
    ZELA: Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) (clinicaltrials.gov)
    P2/3, N=366, Recruiting, Airway Therapeutics, Inc. | Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Mar 2028
    Enrollment open • Trial primary completion date
    2ms
    TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 (clinicaltrials.gov)
    P=N/A, N=1178, Completed, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Completed | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date